China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) saw a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 28,225 shares, a decrease of 96.1% from the October 15th total of 721,044 shares. Currently, 564.5% of the company’s shares are short sold. Based on an average trading volume of 716,620 shares, the days-to-cover ratio is currently 0.0 days.
China SXT Pharmaceuticals Stock Down 7.1%
China SXT Pharmaceuticals stock traded down $0.22 during mid-day trading on Tuesday, hitting $2.88. 92,825 shares of the company’s stock were exchanged, compared to its average volume of 499,381. China SXT Pharmaceuticals has a fifty-two week low of $2.71 and a fifty-two week high of $8,375,880.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94. The company’s 50 day simple moving average is $127.92 and its 200-day simple moving average is $12,490.24.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Weiss Ratings downgraded shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday. Wall Street Zen raised shares of China SXT Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Read Our Latest Stock Analysis on China SXT Pharmaceuticals
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine (TCM) products. The company produces herbal formulations intended for use in the treatment and management of various health conditions, as well as products positioned for general wellness and health maintenance. Its product portfolio includes prescription medicines, over-the-counter medicines and dietary supplements. The company’s offerings are based on traditional Chinese medicinal practices and may be provided in forms such as herbal extracts, pills and other finished formulations.
See Also
- Five stocks we like better than China SXT Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
